Demonstration of different contractile mechanisms for angiotensin II and des-Asp1-angiotensin II in rabbit aortic strips.
Evidence of selective inhibition, differences in dose-response relationships, and cross-tachyphylaxis studies suggest that separate receptors and/or mechanisms may be involved in responses to angiotensin (Ang), [Sar1]Ang II, and Ang III (= des-Asp1-Ang II). The extracellular Ca2+ requirement for contractile responses induced by angiotensin peptides and norepinephrine was determined in rabbit aortic strips. Responses to K+ and [Sar1]Ang II were attenuated markedly by treatment with SKF-525A, verapamil, or Ca2+-free buffer. The response to Ang II was not impaired by verapamil, was blocked partially by SKF-525A, and was reduced markedly in Ca2+-free medium. Norepinephrine- and Ang III-induced contractions were not dependent on extracellular Ca2+. K+, Ang II, and [Sar1]Ang II required extracellular Ca2+ to induce contraction of the rabbit aorta. The data indicate that Ang III may have a mechanism of action that differs from that of [Sar1]Ang II and Ang II.
D000804:Angiotensin II / Q000031:analogs & derivatives* / Q000494:pharmacology*; D000805:Angiotensin III / Q000494:pharmacology*; D000818:Animals; D001011:Aorta; D002118:Calcium / Q000494:pharmacology*; D066298:In Vitro Techniques; D009119:Muscle Contraction / Q000187:drug effects*; D009638:Norepinephrine / Q000494:pharmacology; D011335:Proadifen / Q000494:pharmacology; D011817:Rabbits; D011941:Receptors, Adrenergic / Q000187:drug effects; D011945:Receptors, Angiotensin / Q000187:drug effects; D012504:Saralasin / Q000494:pharmacology; D014700:Verapamil / Q000494:pharmacology
D011941:Receptors, Adrenergic; D011945:Receptors, Angiotensin; D000804:Angiotensin II; D000805:Angiotensin III; D011335:Proadifen; D014700:Verapamil; D012504:Saralasin; D002118:Calcium; D009638:Norepinephrine
J Pharmacol Exp Ther. 1976 Jun;197(3):575-81
6785
Eur J Pharmacol. 1976 Sep;39(1):101-7
183963
J Clin Invest. 1977 Mar;59(3):528-35
190270
Circ Res. 1977 Aug;41(2):231-8
194729
J Clin Endocrinol Metab. 1975 Mar;40(3):530-3
234979
Am J Physiol. 1975 May;228(5):1423-30
236670
Mayo Clin Proc. 1977 Jul;52(7):446-8
875469
Circ Res. 1975 Sep;37(3):350-8
1157223
J Pharmacol Exp Ther. 1974 Nov;191(2):241-51
4153724
Circ Res. 1966 Jun;18(6):641-9
4286906
Circ Res. 1966 Aug;19(2):247-54
4288083
J Pharmacol Exp Ther. 1966 Sep;153(3):466-70
4288410
Arch Int Pharmacodyn Ther. 1967 Aug;168(2):304-11
4292827
J Pharmacol Exp Ther. 1968 Jan;159(1):129-45
4296170
J Pharmacol Exp Ther. 1970 Sep;174(3):500-8
4318489
Circ Res. 1972 Feb;30(2):196-204
4334415
J Pharmacol Exp Ther. 1974 Jan;188(1):222-8
4358436
Klin Wochenschr. 1971 Jan;49(1):32-41
5545957
J Pharmacol Exp Ther. 1953 Jun;108(2):129-43
13062084
Am J Physiol. 1962 Nov;203:849-52
14015437
Am J Physiol. 1964 Jan;206:211-7
14111443
Science. 1963 Feb 15;139(3555):597-9
17788298